复方磺胺甲噁唑对中重度特发性肺纤维化患者死亡、肺移植或住院的影响:EME-TIPAC随机临床试验
这项双盲安慰剂对照随机试验纳入342例中重度特发性肺纤维化(IPF)患者,评估口服复方磺胺甲噁唑(960 mg每日两次)与安慰剂的疗效。
要点
- 复方磺胺甲噁唑未降低中重度IPF患者死亡、肺移植或非择期住院的复合终点风险。
- 两组不良事件常见,复方磺胺甲噁唑组恶心、呕吐、皮疹例数较多,安慰剂组腹泻例数较多。
- 不推荐对中重度IPF患者常规使用复方磺胺甲噁唑以改善上述硬终点。
核心结论
- 在中重度IPF患者中,口服复方磺胺甲噁唑与安慰剂相比未降低死亡、肺移植或非择期住院的复合终点。
研究设计与样本
- 双盲、安慰剂对照、平行随机试验,在英国39家间质性肺病专科中心开展,2015年4月至2019年4月。
- 共纳入342例IPF患者,随机接受口服复方磺胺甲噁唑960 mg每日两次(n=170)或匹配安慰剂(n=172),疗程12至42个月。
- 所有患者每日口服5 mg叶酸。
- 入组条件包括呼吸困难(医学研究理事会呼吸困难量表评分>1)和肺功能受损(用力肺活量≤75%预计值)。
主要发现
- 其他事件结局、肺功能及患者报告结局均无统计学显著差异。
- 复方磺胺甲噁唑组报告696例不良事件,包括恶心89例、腹泻52例、呕吐28例、皮疹31例。
- 安慰剂组报告640例不良事件,包括恶心67例、腹泻84例、呕吐20例、皮疹20例。
临床怎么用
- 对于中重度IPF患者,不应期望复方磺胺甲噁唑能改善死亡、肺移植或非择期住院的复合终点。
- 处方复方磺胺甲噁唑时需关注恶心、呕吐、皮疹等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options. Patients with IPF have altered lung microbiota, with bacterial burden within the lungs associated with mortality; previous studies have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole). OBJECTIVE: To determine the efficacy of co-trimoxazole in patients with moderate and severe IPF. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, parallel randomized trial of 342 patients with IPF, breathlessness (Medical Research Council dyspnea scale score >1), and impaired lung function (forced vital capacity ≤75% predicted) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (first patient visit) and April 2019 (last patient follow-up). INTERVENTIONS: Study participants were randomized to receive 960 mg of oral co-trimoxazole twice daily (n = 170) or matched placebo (n = 172) for between 12 and 42 months. All patients received 5 mg of folic acid orally once daily. MAIN OUTCOMES AND MEASURES: The primary outcome was time to death (all causes), lung transplant, or first nonelective hospital admission. There were 15 secondary outcomes, including the individual components of the primary end point respiratory-related events, lung function (forced vital capacity and gas transfer), and patient-reported outcomes (Medical Research Council dyspnea scale, 5-level EuroQol 5-dimension questionnaire, cough severity, Leicester Cough Questionnaire, and King's Brief Interstitial Lung Disease questionnaire scores). RESULTS: Among 342 individuals who were randomized (mean age, 71.3 years; 46 [13%] women), 283 (83%) completed the trial. The median (interquartile range) duration of follow-up was 1.02 (0.35-1.73) years. Events per person-year of follow-up among participants randomized to the co-trimoxazole and placebo groups were 0.45 (84/186) and 0.38 (80/209), respectively, with a hazard ratio of 1.2 ([95% CI, 0.9-1.6]; P = .32). There were no statistically significant differences in other event outcomes, lung function, or patient-reported outcomes. Patients in the co-trimoxazole group had 696 adverse events (nausea [n = 89], diarrhea [n = 52], vomiting [n = 28], and rash [n = 31]) and patients in the placebo group had 640 adverse events (nausea [n = 67], diarrhea [n = 84], vomiting [n = 20], and rash [n = 20]). CONCLUSIONS AND RELEVANCE: Among patients with moderate or severe IPF, treatment with oral co-trimoxazole did not reduce a composite outcome of time to death, transplant, or nonelective hospitalization compared with placebo. TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN17464641.
引用
- Wilson AM, Clark AB, Cahn T, et al. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial. JAMA. 2020. PMID: 33289822. doi:10.1001/jama.2020.22960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。